WO2004035803A3 - Method and nucleic acids for the treatment of breast cell proliferative disorders - Google Patents

Method and nucleic acids for the treatment of breast cell proliferative disorders Download PDF

Info

Publication number
WO2004035803A3
WO2004035803A3 PCT/EP2003/010881 EP0310881W WO2004035803A3 WO 2004035803 A3 WO2004035803 A3 WO 2004035803A3 EP 0310881 W EP0310881 W EP 0310881W WO 2004035803 A3 WO2004035803 A3 WO 2004035803A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell proliferative
treatment
nucleic acids
proliferative disorders
breast cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/010881
Other languages
French (fr)
Other versions
WO2004035803A2 (en
WO2004035803A9 (en
Inventor
John Foekens
Nadia Harbeck
Thomas Koenig
Sabine Maier
John Martens
Fabian Model
Inko Nimmrich
Tamas Rujan
Armin Schmitt
Manfred Schmitt
Maxime P Look
Almuth Marx
Heinz Hoefler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epigenomics AG
Original Assignee
Epigenomics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2002145779 external-priority patent/DE10245779A1/en
Priority claimed from DE2003117955 external-priority patent/DE10317955A1/en
Priority to US10/517,741 priority Critical patent/US8101359B2/en
Priority to AU2003300504A priority patent/AU2003300504B2/en
Priority to AT03808704T priority patent/ATE437962T1/en
Priority to EP03808704A priority patent/EP1554407B1/en
Priority to CA002500255A priority patent/CA2500255A1/en
Priority to JP2005501274A priority patent/JP4649331B2/en
Priority to DE60328618T priority patent/DE60328618D1/en
Application filed by Epigenomics AG filed Critical Epigenomics AG
Publication of WO2004035803A2 publication Critical patent/WO2004035803A2/en
Publication of WO2004035803A9 publication Critical patent/WO2004035803A9/en
Publication of WO2004035803A3 publication Critical patent/WO2004035803A3/en
Priority to US11/011,332 priority patent/US20060024684A1/en
Anticipated expiration legal-status Critical
Priority to US11/628,703 priority patent/US20090269736A1/en
Priority to US13/352,238 priority patent/US20120184455A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for predicting the response of a subject with a cell proliferative disorder of the breast tissues, to endocrine treatment.
PCT/EP2003/010881 2002-10-01 2003-10-01 Method and nucleic acids for the treatment of breast cell proliferative disorders Ceased WO2004035803A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US10/517,741 US8101359B2 (en) 2002-10-01 2003-10-01 Method for determining risk of relapse of breast cancer following tamoxifen adjuvant therapy
AU2003300504A AU2003300504B2 (en) 2002-10-01 2003-10-01 Method and nucleic acids for the improved treatment of breast cell proliferative disorders
AT03808704T ATE437962T1 (en) 2002-10-01 2003-10-01 METHOD FOR THE TREATMENT OF PROLIFERATIVE DISEASES OF BREAST CELLS
EP03808704A EP1554407B1 (en) 2002-10-01 2003-10-01 Method for the treatment of breast cell proliferative disorders
CA002500255A CA2500255A1 (en) 2002-10-01 2003-10-01 Method and nucleic acids for the treatment of breast cell proliferative disorders
JP2005501274A JP4649331B2 (en) 2002-10-01 2003-10-01 Improved treatment method and nucleic acid for breast cell proliferation disorder
DE60328618T DE60328618D1 (en) 2002-10-01 2003-10-01 PROCESS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS OF BREAST CELLS
US11/011,332 US20060024684A1 (en) 2002-10-01 2004-12-13 Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
US11/628,703 US20090269736A1 (en) 2002-10-01 2005-06-06 Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
US13/352,238 US20120184455A1 (en) 2002-10-01 2012-01-17 Method and Nucleic Acids for the Improved Treatment of Breast Cell Proliferative Disorders

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE10245779.4 2002-10-01
DE2002145779 DE10245779A1 (en) 2002-10-01 2002-10-01 Predicting responsiveness of a subject with breast cell proliferative disorder, useful for treating or differentiating breast cell proliferative disorders comprises analyzing methylation pattern of a genomic DNA from the subject
DE10300096.8 2003-01-07
DE10300096 2003-01-07
DE2003117955 DE10317955A1 (en) 2003-04-17 2003-04-17 Predicting responsiveness of a subject with breast cell proliferative disorder, useful for treating or differentiating breast cell proliferative disorders comprises analyzing methylation pattern of a genomic DNA from the subject
DE10317955.0 2003-04-17

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/517,741 A-371-Of-International US8101359B2 (en) 2002-10-01 2003-10-01 Method for determining risk of relapse of breast cancer following tamoxifen adjuvant therapy
US11/011,332 Continuation-In-Part US20060024684A1 (en) 2002-10-01 2004-12-13 Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
US13/352,238 Division US20120184455A1 (en) 2002-10-01 2012-01-17 Method and Nucleic Acids for the Improved Treatment of Breast Cell Proliferative Disorders

Publications (3)

Publication Number Publication Date
WO2004035803A2 WO2004035803A2 (en) 2004-04-29
WO2004035803A9 WO2004035803A9 (en) 2004-06-10
WO2004035803A3 true WO2004035803A3 (en) 2004-10-14

Family

ID=32110469

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/010881 Ceased WO2004035803A2 (en) 2002-10-01 2003-10-01 Method and nucleic acids for the treatment of breast cell proliferative disorders

Country Status (9)

Country Link
US (2) US8101359B2 (en)
EP (2) EP2157191B1 (en)
JP (1) JP4649331B2 (en)
AT (1) ATE437962T1 (en)
AU (2) AU2003300504B2 (en)
CA (1) CA2500255A1 (en)
DE (1) DE60328618D1 (en)
ES (2) ES2330328T3 (en)
WO (1) WO2004035803A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE437962T1 (en) 2002-10-01 2009-08-15 Epigenomics Ag METHOD FOR THE TREATMENT OF PROLIFERATIVE DISEASES OF BREAST CELLS
US20060024684A1 (en) * 2002-10-01 2006-02-02 Epigenomics Ag Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
US20090269736A1 (en) * 2002-10-01 2009-10-29 Epigenomics Ag Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
AU2004237861B2 (en) * 2003-12-11 2010-04-29 Epigenomics Ag Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
EP1561821B1 (en) 2003-12-11 2011-02-16 Epigenomics AG Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
WO2005123945A2 (en) * 2004-06-21 2005-12-29 Epigenomics Ag Epigenetic markers for the treatment of breast cancer
CA2593546A1 (en) * 2004-12-02 2006-07-06 Epigenomics Ag Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
JP2008523073A (en) * 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Selection of patients for treatment with HER inhibitors
EP2272984B1 (en) * 2005-02-01 2012-06-20 John Wayne Cancer Institute Use of ID4 for diagnosis and treatment of cancer
EP1693468A1 (en) 2005-02-16 2006-08-23 Epigenomics AG Method for determining the methylation pattern of a polynucleic acid
US7932027B2 (en) 2005-02-16 2011-04-26 Epigenomics Ag Method for determining the methylation pattern of a polynucleic acid
KR20130021400A (en) 2005-04-15 2013-03-05 에피제노믹스 아게 Methods and nucleic acids for analyses of cellular proliferative disorders
WO2006113770A1 (en) 2005-04-15 2006-10-26 Epigenomics Ag A method for providing dna fragments derived from a remote sample
WO2006131391A1 (en) * 2005-06-10 2006-12-14 Epigenomics Ag Prognostic assay for prediction of treatment response and/or survival of breast cell proliferative disorder patients
WO2006133866A2 (en) * 2005-06-11 2006-12-21 Epigenomics Ag Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
WO2007039128A1 (en) * 2005-09-21 2007-04-12 Epigenomics Ag Markers for the prediction of outcome of anthracycline treatment
US20080254470A1 (en) * 2005-10-03 2008-10-16 Epigenomics Ag Methods and Nucleic Acids For the Analysis of Gene Expression Associated With the Prognosis of Cell Proliferative Disorders
WO2007039291A2 (en) * 2005-10-03 2007-04-12 Epigenomics Ag Methods, apparatus and nomograms to determine prostate cancer progression
WO2007047699A1 (en) * 2005-10-17 2007-04-26 Epigenomics Ag Method and nucleic acids for the improved treatment of breast cancers
TW200808360A (en) 2006-04-13 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
EP2484778A3 (en) 2006-04-17 2012-10-10 Epigenomics AG Methods and nucleic acids for the detection of colorectal cell proliferative disorders
WO2007137873A1 (en) * 2006-06-01 2007-12-06 Epigenomics Ag Method and nucleic acids for the improved treatment of breast cancers
EP2059171A2 (en) * 2006-08-31 2009-05-20 Koninklijke Philips Electronics N.V. Imaging system
WO2009027978A1 (en) * 2007-08-30 2009-03-05 Hadasit Medical Research Services & Development Ltd. NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
MX2010003718A (en) * 2007-10-19 2010-04-21 Genentech Inc ANTI-TENB2 ANTIBODIES PRODUCED BY CISTEINE ENGINEERING AND PHARMACO AND ANTIBODY CONJUGATES.
KR101497035B1 (en) * 2010-04-26 2015-02-27 주식회사 녹십자 Tumor-specific promoter and oncolytic virus vector comprising the same
WO2016041010A1 (en) * 2014-09-15 2016-03-24 Garvan Institute Of Medical Research Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor
EP4063516A1 (en) * 2014-09-26 2022-09-28 Janssen Pharmaceutica NV Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
CN108138235B (en) 2015-08-31 2022-04-15 梅约医药教育及研究基金会 Detection of gastric tumors
US11685955B2 (en) 2016-05-16 2023-06-27 Dimo Dietrich Method for predicting response of patients with malignant diseases to immunotherapy
DE102016005947B3 (en) 2016-05-16 2017-06-08 Dimo Dietrich A method for estimating the prognosis and predicting the response to immunotherapy of patients with malignant diseases
CN116445593A (en) 2016-08-10 2023-07-18 格里尔公司 Method for determining a methylation profile of a biological sample
CN112585282A (en) * 2018-07-26 2021-03-30 北京艾克伦医疗科技有限公司 Methods and kits for identifying breast cancer status
EP3948292A4 (en) * 2019-04-03 2023-01-18 Mayo Foundation for Medical Education and Research DETECTION OF PANCREATIC DUCT ADENOCARCINOMA IN PLASMA
US20240117444A1 (en) * 2021-02-12 2024-04-11 Mammogen, Inc. Biomarkers for the diagnosis of breast cancer
CN116004830B (en) * 2023-01-05 2023-08-11 山东大学 Biomarker for ovarian cancer and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068912A2 (en) * 2000-03-15 2001-09-20 Epigenomics Ag Diagnosis of diseases associated with tumor suppressor genes and oncogenes
EP1167975A1 (en) * 2000-06-22 2002-01-02 Universite Rene Descartes (Paris V) Compositions and methods for detecting, treating or predicting the response of tumor cells to endocrine therapy.
WO2002059347A2 (en) * 2001-01-26 2002-08-01 The Johns Hopkins University School Of Medicine Aberrantly methylated genes as markers of breast malignancy
WO2003052135A2 (en) * 2001-12-14 2003-06-26 Epigenomics Ag Method and nucleic acids for the analysis of a lung cell proliferative disorder

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
SE501439C2 (en) 1993-06-22 1995-02-13 Pharmacia Lkb Biotech Method and apparatus for analyzing polynucleotide sequences
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
AU1061395A (en) 1993-11-30 1995-06-19 Mcgill University Inhibition of dna methyltransferase
US5871917A (en) 1996-05-31 1999-02-16 North Shore University Hospital Research Corp. Identification of differentially methylated and mutated nucleic acids
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
DE19754482A1 (en) 1997-11-27 1999-07-01 Epigenomics Gmbh Process for making complex DNA methylation fingerprints
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
US6783933B1 (en) 1999-09-15 2004-08-31 The Johns Hopkins University School Of Medicine CACNA1G polynucleotide, polypeptide and methods of use therefor
US6596488B2 (en) 2000-03-30 2003-07-22 City Of Hope Tumor suppressor gene
EP1274865B1 (en) * 2000-04-06 2007-02-14 Epigenomics AG Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis
WO2002000926A2 (en) * 2000-06-30 2002-01-03 Epigenomics Ag Diagnosis of diseases associated with signal transduction
US6562171B1 (en) * 2000-10-10 2003-05-13 Eastman Kodak Company Method for making a two sided image
EP1410304A2 (en) * 2001-03-26 2004-04-21 Epigenomics AG Method for epigenetic feature selection
US7125663B2 (en) * 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
US7118870B2 (en) * 2001-09-28 2006-10-10 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Detection of fecal contamination using nucleic acid molecules that recognize bacterial 16S rDNA sequences
ATE437962T1 (en) 2002-10-01 2009-08-15 Epigenomics Ag METHOD FOR THE TREATMENT OF PROLIFERATIVE DISEASES OF BREAST CELLS
DE10245779A1 (en) 2002-10-01 2004-04-29 Epigenomics Ag Predicting responsiveness of a subject with breast cell proliferative disorder, useful for treating or differentiating breast cell proliferative disorders comprises analyzing methylation pattern of a genomic DNA from the subject
DE10317955A1 (en) 2003-04-17 2004-11-25 Epigenomics Ag Predicting responsiveness of a subject with breast cell proliferative disorder, useful for treating or differentiating breast cell proliferative disorders comprises analyzing methylation pattern of a genomic DNA from the subject
AU2004237861B2 (en) * 2003-12-11 2010-04-29 Epigenomics Ag Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068912A2 (en) * 2000-03-15 2001-09-20 Epigenomics Ag Diagnosis of diseases associated with tumor suppressor genes and oncogenes
EP1167975A1 (en) * 2000-06-22 2002-01-02 Universite Rene Descartes (Paris V) Compositions and methods for detecting, treating or predicting the response of tumor cells to endocrine therapy.
WO2002059347A2 (en) * 2001-01-26 2002-08-01 The Johns Hopkins University School Of Medicine Aberrantly methylated genes as markers of breast malignancy
WO2003052135A2 (en) * 2001-12-14 2003-06-26 Epigenomics Ag Method and nucleic acids for the analysis of a lung cell proliferative disorder

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BRATTSAND G: "Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors.", BRITISH JOURNAL OF CANCER. AUG 2000, vol. 83, no. 3, August 2000 (2000-08-01), pages 311 - 318, XP002280240, ISSN: 0007-0920 *
CURMI P A ET AL: "Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 82, no. 1, 2000, pages 142 - 150, XP002908452, ISSN: 0007-0920 *
GITAN RAAD S ET AL: "Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis", GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 12, no. 1, January 2002 (2002-01-01), pages 158 - 164, XP002208051, ISSN: 1088-9051 *
HUANG TIM HUI-MING ET AL: "Methylation profiling of CpG islands in human breast cancer cells", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 8, no. 3, March 1999 (1999-03-01), pages 459 - 470, XP002175857, ISSN: 0964-6906 *
LAPIDUS R G ET AL: "Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. MAY 1996, vol. 2, no. 5, May 1996 (1996-05-01), pages 805 - 810, XP008030590, ISSN: 1078-0432 *
MARTENS J W M ET AL: "Epigenetic signature predicts failure of endocrine therapy in patients with recurrent breast cancer.", BREAST CANCER RESEARCH AND TREATMENT, vol. 82, no. Supplement 1, 2003, 26th Annual San Antonio Breast Cancer Symposium;San Antonio, TX, USA; December 03-06, 2003, pages S72, XP008030522, ISSN: 0167-6806 (ISSN print) *
OTTAVIANO Y L ET AL: "Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 54, no. 10, 15 May 1994 (1994-05-15), pages 2552 - 2555, XP000999429, ISSN: 0008-5472 *
YAN P S ET AL: "Dissecting complex epigenetic alterations in breast cancer using CpG Island microarrays", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 23, 1 December 2001 (2001-12-01), pages 8375 - 8380, XP002243660, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2004035803A2 (en) 2004-04-29
DE60328618D1 (en) 2009-09-10
EP2157191A2 (en) 2010-02-24
US20120184455A1 (en) 2012-07-19
US20060121467A1 (en) 2006-06-08
EP2157191A3 (en) 2010-06-09
AU2009251178A1 (en) 2010-01-21
EP1554407B1 (en) 2009-07-29
ATE437962T1 (en) 2009-08-15
JP2006515513A (en) 2006-06-01
EP2157191B1 (en) 2013-12-25
CA2500255A1 (en) 2004-04-29
AU2003300504A1 (en) 2004-05-04
ES2330328T3 (en) 2009-12-09
JP4649331B2 (en) 2011-03-09
ES2447566T3 (en) 2014-03-12
EP1554407A2 (en) 2005-07-20
AU2003300504B2 (en) 2009-10-01
US8101359B2 (en) 2012-01-24
WO2004035803A9 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
WO2004035803A3 (en) Method and nucleic acids for the treatment of breast cell proliferative disorders
WO2005059172A3 (en) Method and nucleic acids for the improved treatment of breast cell proliferative disorders
WO2002077272A3 (en) Methods and nucleic acids for the analysis of hematopoietic cell proliferative disorders
WO2002002808A3 (en) Method and nucleic acids for the analysis of astrocytomas
WO2001077375A8 (en) Diagnosis of diseases associated with gene regulation
WO2001068912A3 (en) Diagnosis of diseases associated with tumor suppressor genes and oncogenes
WO2003072821A3 (en) Method and nucleic acids for the analysis of a colon cell proliferactive disorder
WO2003052135A3 (en) Method and nucleic acids for the analysis of a lung cell proliferative disorder
WO2004020662A3 (en) Method and nucleic acids for the analysis of breast cell proliferative disorders
WO2005001141A8 (en) Methods and nucleic acids for analyses of colorectal cell proliferative disorders
WO2003014388A3 (en) Method and nucleic acids for the analysis of colon cancer
WO2002103042A3 (en) Method and nucleic acids for the differentiation of prostate tumors
WO2002046454A3 (en) Diagnosis of diseases associated with angiogenesis by determining the methylation of genes associated with angiogenesis
WO2003044226A3 (en) Method and nucleic acids for the analysis of a lymphoid cell proliferative disorder
WO2002036814A3 (en) Diagnosis of diseases associated with cdk4 by determining the methylation state of the cdk4
WO2005001140A3 (en) Methods and nucleic acids for the analysis of colon cell proliferative disorders
WO2002103041A3 (en) Method and nucleic acids for the differentiation of prostate and renal carcinomas
AU2003206236A1 (en) Dnas which encode rna polymerase beta-subunit gene of legionella species, primers specific to the dnas and discrimination method for legionella species by using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 78, CLAIMS, REPLACED BY A NEW PAGE 78;

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003300504

Country of ref document: AU

Ref document number: 2005501274

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2500255

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003808704

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003808704

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006121467

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10517741

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10517741

Country of ref document: US